د.عبدالله علي الشرم

🧠📊 dMMR/MSI-H mCRC: mono vs dual IO ✔️ PD-1 monotherapy → ORR ↑ vs CT + G3-4 toxicity ↓ ✔️ Nivo+ipi → ORR ↑ vs PD-1 alone ⚠️ Toxicity ↑ with dual IO, without consistent OS benefit across trials 💡 Personalization remains key in 1L MSI-H mCRC 🔗 doi.org/10.1186/s12885… @OncoAlert

KEYNOTE-811 6-year follow-up continues to strengthen the role of pembrolizumab + trastuzumab + chemotherapy in HER2+ advanced gastric/GEJ cancer. • OS: 20.0 vs 16.8 months • ORR: 72.6% vs 60.1% • Strongest benefit in PD-L1 CPS ≥1 disease Durable benefit. Long follow-up. Practice-changing trial. #ASCO2026 #GastricCancer #GIOncology #HER2 #Immunotherapy #MVOnco

🧬 THE 10 MOST IMPORTANT GU CANCER TRIALS OF #ASCO26 🎯 PROSTATE CANCER: INTENSIFICATION vs QUALITY OF LIFE 1️⃣ PROTEUS Perioperative apalutamide + ADT in high-risk localized prostate cancer Can aggressive ARPI intensification improve curative outcomes? 2️⃣ ARACOG (5005) Darolutamide vs enzalutamide cognitive effects One of the most important patient-centered prostate datasets of the meeting. 3️⃣ PEACE-3 Radium-223 + enzalutamide in bone-metastatic mCRPC Can alpha-emitter combinations improve survival meaningfully? 4️⃣ Mevrometostat + Enzalutamide Phase III EZH2 inhibition strategy in advanced prostate cancer Targeting lineage plasticity and ARPI resistance. BLADDER & UROTHELIAL CANCER: THE SEQUENCING ERA 5️⃣ KEYNOTE-B15 / EV-304 Perioperative EV + pembrolizumab vs chemotherapy in MIBC Could this finally replace cisplatin-based perioperative therapy? 6️⃣ IMvigor011 ctDNA-guided adjuvant atezolizumab in urothelial cancer One of the definitive MRD/liquid biopsy trials at ASCO26. 7️⃣ POTOMAC (4624) IO + BCG in high-risk NMIBC A major frontline positioning question. 8️⃣ EV-302 Long-Term Follow-Up (4507) Extended outcomes for EV + pembrolizumab in metastatic urothelial cancer Long-term survival and toxicity data matter now. RCC & PRECISION ADJUVANT THERAPY 9️⃣ LITESPARK-022 Adjuvant pembrolizumab + belzutifan in high-risk ccRCC Can HIF-2α inhibition improve adjuvant outcomes? 🔟 KEYNOTE-564 ctDNA Analysis Who truly benefits from adjuvant pembrolizumab in RCC? Potentially critical for avoiding overtreatment. #GUOnc #OncTwitter #ASCO26 #ProstateCancer #BladderCancer #MedTwitter @ASCO @myesmo @esmo_open @Larvol

PD1-PDL1 axis #immumopath #ICI #PD1 #PDL1 #CTLA4 #pathology #pathognosis

🧬 FAPI PET is redefining the future of cancer imaging. Unlike FDG PET, which visualizes tumor glucose metabolism, FAPI PET maps the tumor microenvironment — especially cancer-associated fibroblasts (CAFs) and stromal activity. Why this matters clinically 👇 ✅ Better tumor-to-background contrast ✅ Superior detection of peritoneal disease ✅ Improved visualization of desmoplastic tumors ✅ Better assessment of low-FDG tumors ✅ Potential role in radiotherapy contouring ✅ Emerging theranostic applications (^177Lu-FAPI) The shift in oncology imaging is happening: ➡️ From “tumor metabolism imaging” ➡️ To “tumor ecosystem imaging” #FAPIPET #PETCT #NuclearMedicine #MedicalOncology #CancerImaging #Radiology #Oncology #PrecisionOncology #Theranostics #RadiationOncology #PancreaticCancer #GastricCancer #BreastCancer #HeadAndNeckCancer #CancerResearch #DrRupamManna #CancerConceptsExplained

Tackling similarities and differences in global practice guidelines for gastric cancer: a review on the latest Taiwan guidelines with Asia-Pacific, European and US guidelines | Gastric Cancer | Springer Nature Link link.springer.com/article/10.100…

LAPIS: A Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Neoadjuvant Pamrevlumab With Chemotherapy for Patients With Locally Advanced Pancreatic Cancer | JCO Oncology Advances ascopubs.org/doi/10.1200/OA…

@mmoazin فخورين فيك د ماهر الف الف مبروك هذا الانجاز تستاهل كل خير

بفضل الله، ثم بدعم قيادتنا الرشيدة، تشرفت بأن أكون أول جراح سعودي يُجري عملية جراحية روبوتية عن بُعد بين مدينتين في الصين، من شنجن إلى بكين، بمسافة تجاوزت 1900 كيلومتر، وبتأخير تقني لم يتجاوز 73 ملي ثانية.خالص الشكر والعرفان لمولاي خادم الحرمين الشريفين وسمو سيدي ولي العهد الأمين

First preclinical publication of daraxonrasib, april 2024 👇 Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy | Nature nature.com/articles/s4158…

أمس الاثنين بيعت رابع أغلى لوحة فنّية في تاريخ المزادات العلنية بالعالم! لوحة "1948,Number 7A" للفنان الأمريكي جاكسون بولوك خلال المزاد تنافس 4 أثرياء بشكل سرّي عبر الهاتف..قبل أن تباع بمبلغ 181.2 مليون دولار لمشتري مجهول  عاد المفارقة العجيبة ان بولوك نفسه -الرسام- مات وسط مشاكل مالية وعدم استقرار 🤷‍♂️ وكان يعاني من اضطرابات نفسية شديدة وإدمان على الكحول

Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French genomic medicine initiative @JHepatology doi.org/10.1016/j.jhep… 👉Integrating WGS, WES and RNAseq key to identify actionable genomic alterations @myESMO @EASLedu @ILCAnews

Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma @JHepatology doi.org/10.1016/j.jhep… 👉Disappointing, we need to do better... @myESMO @EASLedu @ILCAnews

JUST IN: @FDA approves adjuvant PD-L1 inhibitor Atezolizumab in Muscle-Invasive Bladder Cancer post surgery & ctDNA MRD (+) by @NateraGenetics Signatera CDx approved as companion diagnostic. MRD-guided adjuvant therapy is moving into practice in Bladder Cancer! FDA link: fda.gov/drugs/resource…

🔵Second-Line TKIs after 1L IO-based Treatment in Advanced HCC @JHEP_Reports ➡️Our reconstructed IPD meta-analysis ➡️Mainly after atezo-bev 🚨Sorafenib seem to be less effective than lenvatinib and regorafenib ✅Lenvatinib seem to have better efficacy ❓Cabozantinib may be promosing, but needs more data ⚠️Results are exploratory, prospective trials are needed 👉doi.org/10.1016/j.jhep… 🙏Many thanks to all co-authors and mentors, especially Dr. Bouattour #cancer #oncology #liver #hcc #hepatocellular #MedX @OncoAlert

This is an absolutely outstanding review on the management of patients with metastatic gastric cancer. I may have posted about this review before but it is so good that it deserves another round of applause... Thanks @KlempnerSam @YJanjigianMD @amalsargsyan and all the other co-authors I could not find on X... Sorry AI, I love you but you are just not there yet. True content experts writing a practical review still beat you easily. This should be a required read for all who take care of patients with gastric cancer. nature.com/articles/s4157…

First images from the GE Omni 128 cm Total Body PET/CT 🚀 The new scanner detected a <5 mm local recurrence of prostate cancer missed by standard PSMA PET/CT - despite 79% shorter acquisition ⏱️ Delayed imaging boosted lesion uptake and informed dose-painted salvage RT 🎯 @JournalofNucMed @PeterMacCC @declangmurphy @_ShankarSiva jnm.snmjournals.org/content/early/…

@TalhaBadarMD @syed_abutalibmd Well done brother, we are very proud of you 👏

Happy to share our chapter in the 2nd edition of Classical Hematology: “Hemostasis Disturbances in Acute Leukemias and Myelodysplastic Neoplasms” Honored to collaborate with Syed Ali Abutalib and Jean M. Connors on this practical Q&A-based review covering: 🔹 Bleeding & thrombosis in acute leukemias/MDS 🔹 Pegasparaginase-associated coagulopathy 🔹 DIC, hypofibrinogenemia & CNS thrombosis 🔹 Real-world diagnostic and management challenges Grateful to contribute to this outstanding educational resource in hematology. #Leusm #mdssm #Thrombosis #Hemostasis #MedEd #AML #ALL

Impact of treatment discontinuation among patients with microsatellite instability or mismatch repair-deficient metastatic colorectal cancer treated with immune checkpoint inhibitors - ESMO Open esmoopen.com/article/S2059-…

Real-world study (n=390). 6mo adjuvant chemo in pT4N0 colon cancer increased 3y OS to 98% vs 62% without; RFS: 78% vs 54%. Oxaliplatin-based doublets cut death (HR 0.21) & recurrence (HR 0.48). MSI (25%) had no impact. R0 resection in 97%. esmoopen.com/article/S2059-…

New prognostic and predictive scoring systems for colorectal cancer liver metastases esmoopen.com/article/S2059-… #GIpath #liverpath